Ciara Kennedy, Ph.D., is president and CEO of Amplyx Pharmaceuticals, Inc. Initially, Ciara Kennedy was appointed COO of Amplyx in October 2015, following a successful, $50 million Series B financing. Prior to joining Amplyx, Dr. Kennedy served as COO at Lumena Pharmaceuticals until the company was acquired by Shire Pharmaceuticals. Prior to Lumena, she was VP of operations and Sr Director of strategy and corporate development at Cypress Bioscience Inc., where she played a key role in obtaining FDA approval for Savella, a therapy for fibromyalgia. Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland, and continued her research at the Sanford Burnham Prebys Medical Discovery Institute. In 2004,she became a member of the inaugural class of the Rady School of Management at University of California, San Diego. She graduated with a Masters of Business Administration in 2006.